Skip to main content

Table 3 PV Treatment Patterns and Concomitant Medications During the Follow-Up Period

From: Cytoreductive treatment patterns among US veterans with polycythemia vera

Treatment, n (%) Patients With PV (N = 7718)
PV-related treatmenta
 Pharmacologic cytoreductive treatmentb 1787 (23.2)
  Hydroxyurea 1550 (20.1)
  Anagrelide 206 (2.7)
  Radiophosphorus 132 (1.7)
  Interferon or PEGylated interferon 90 (1.2)
  Busulfan 15 (0.2)
 Phlebotomyc 2531 (32.8)
 Pharmacologic cytoreductive treatment and phlebotomy 688 (8.9)
 No cytoreductive treatment or phlebotomy 4088 (53.0)
 Aspirind 1815 (23.5)
 Antiplatelet agents, not including aspirin 1511 (19.6)
Common concomitant medications
 Antihypertensive agents 6671 (86.4)
  ACE inhibitors 4226 (54.8)
 Antilipid/anticholesterol agents 4882 (63.3)
 Antidiabetic agents 2163 (28.0)
 Anticoagulants 1313 (17.0)
 Inotropic agents 580 (7.5)
 Antiarrhythmic agents 362 (4.7)
  1. ACE angiotensin-converting enzyme, PV polycythemia vera
  2. aRuxolitinib received approval from the US Food and Drug Administration for patients with PV who have had an inadequate response to or are intolerant of hydroxyurea after the end of the study period
  3. bPatients receiving pharmacologic cytoreductive treatment may have also received phlebotomy
  4. cPatients receiving phlebotomy may have also received pharmacologic cytoreductive treatment
  5. dIncludes both prescribed and over-the-counter aspirin and may underrepresent actual aspirin use